Sage Journals: Discover world-class research

Abstract

Medication safety must be tailored to the distinctive issues in residential aged-care facilities (RACFs). The health and functional characteristics of their residents are different to those of hospital inpatients and community-dwelling older adults, and there are unique staffing and management issues. Understanding the aetiology and epidemiology of drug-related problems is vital in developing methods to improve patient safety. In this perspective review, we discuss tools that are used to quantify exposure to ‘high-risk’ medications and their evaluation in residential aged-care settings. Drug withdrawal interventions are described as a potential way to reduce adverse drug events in RACFs. Multidisciplinary professional interventions, education programs and improved communication between health professionals have been shown to improve medication safety in RACFs. Technological advances and other administrative strategies may also improve resident safety. This perspective addresses issues in medication safety facing RACFs and methods to improve the safety of medicines for their residents.

Keywords

inappropriate medications medication safety nursing home pharmacist review residential aged care

Background

Pharmacological therapy is an integral part of modern health management and differs greatly between populations. Different population characteristics mean that safety issues and interventions arising in one setting may not apply to another. Community-dwelling people have multiple factors influencing their medications, including active commitment and responsibility of the patient. In the hospital setting there is more likely to be one set of records and less involvement of the patient. Older people, specifically those who live in residential aged-care facilities (RACFs), have reduced autonomy and exhibit different lifestyle, pharmacokinetic and pharmacodynamic characteristics to either of the aforementioned groups [Hilmer et al. 2007b]. There is very little evidence on the efficacy of medicines in older people living in RACFs. These people have a high risk of adverse drug events (ADEs) as they are likely to have multiple cormorbidities and, hence, multiple medicines, including medicines of a high-risk category [Catania, 1998; Harms and Garrard, 1998]. It is therefore paramount that drug safety, initiated by a multidisciplinary team of health professionals, be a component of patient care in RACFs.

Epidemiology

ADEs cause injuries and are the result of medication errors and adverse drug reactions (ADRs). An ADR is defined as ‘a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function’ [Edwards and Aronson, 2000]. Application of this definition to residents of aged-care facilities is complicated by pharmacokinetic and pharmacodynamic changes that may mean that the doses normally used in man may not be the optimal doses in this population. An early study using retrospective reviews of incident reports reported a prevalence of 50 ADRs from a 700-bed long-term care facility over 1 year (0.60 per 100 resident-months), which was thought to be an underestimate due to the voluntary reporting system [Gurwitz et al. 1994]. In 1997, Gurwitz and colleagues undertook a comprehensive cohort study in 18 nursing homes in the USA investigating ADEs by RACF staff self-report, trained researcher record reviews and independent physician classification [Gurwitz et al. 2000]. They found high ADEs rates of 1.89 per 100 resident-months, with half of these considered preventable.

Studies investigating potentially inappropriate prescriptions (PIPs), a modifiable risk factor for ADEs, showed that 50–70% of nursing home residents had a PIP [Bergman et al. 2007; Rancourt et al. 2004]. A difficulty in assessing RACF ADR and ADE rates, and the interventions that aim to decrease them, is that many studies contain different groups of people from different clinical settings due to the infrastructure of healthcare in that particular region [Kaur et al. 2009]. A large study involving over one million individuals from Canada showed that residents of nursing homes were approximately half as likely to be exposed to those PIPs from the subgroups ‘therapies to always avoid’ and ‘those that are rarely appropriate’ (19/33 PIPs) when compared with community-dwelling older adults (2.3% exposure versus 3.3%, p < 0.001; odds ratio [OR] = 0.52; 95% confidence interval [CI] = 0.49–0.55), despite being on a higher number of distinct drugs [Lane et al. 2004]. The high prevalence of PIPs in RACFs across North America and Europe is reviewed by Ruggiero and colleagues [Ruggiero et al. 2009]. Residents are often already exposed to PIPs prior to admission to RACFs, and risk factors for PIPs appear to be polypharmacy, multiple prescribers, younger age (<80 years) and a low ratio of nurses to residents [Ruggiero et al. 2009].

Risk factors for ADEs give an alternative insight into what causes them. These differ between settings. Factors independently associated with higher risk of an ADE in a nursing home setting are being a new resident (OR = 2.8; 95% CI 1.5–5.2), taking 5–6 (OR = 2.0; 95% CI 1.2–3.2), 7–8 (OR = 2.8, 95% CI 1.7–4.7) or 9 or more (OR = 3.3, 95% CI 1.9–5.6) regularly scheduled medications, and taking an antibiotic or anti-infective (OR = 4.0, 95% CI 2.5–6.2), antipsychotic (OR = 3.2, 95% CI 2.1–4.9) or antidepressant (OR = 1.5, 95% CI 1.1–2.3). Conversely, taking nutrients or supplements is protective against ADEs (OR = 0.42, 95% CI 0.27–0.63) [Field et al. 2001]. For older people in an ambulatory setting, while polypharmacy remains a risk factor for ADEs, there is little overlap with residents of aged care facilities in the specific high-risk drug classes for ADEs [Field et al. 2004]. Amongst hospital inpatients, risk factors for ADEs appear to be features of the illness rather than the medicines [Bates et al. 1999].

Risk assessment tools

In older people, ADRs frequently present as geriatric syndromes [Avorn and Shrank, 2008]. Clinically important outcomes in older people in RACFs include impairments of physical and cognitive function, falls, hospitalization and death. Several tools have been developed to measure the exposure to high-risk medicines in older people, and the associations between such exposure and adverse outcomes has been investigated (Table 1). Interestingly, the associations are not always consistent between older people from different settings.

Table 1.

Tools to measure medication risk in older people.

Tool	Description	Population(s) tested in	Outcome
Expert consensus tools
Beers’ criteria	List of medications considered inappropriate when given to elderly	Community-dwelling, nursing home and hospital-residing older people.	Increase in ADR, hospitalisation and mortality in nursing home residents. Increase of ADR in community dwelling [Laroche et al. 2007; Fick et al. 2003; Beers et al. 1991]
Medication Appropriate Index (MAI)	10 criteria that measure aspects of inappropriate prescribing for each medication	Older ambulatory and primary care adults	Statistically discordant to Beers’ criteria but still predicted ADE risk [Lund et al. 2010; Steinman et al. 2007; Fitzgerald et al. 1997; Hanlon et al. 1992]
Screening Tool for Older Persons’ Prescriptions (STOPP) and Screening Tool to Alert Right Treatment (START) Criteria	To detect potential errors of pre scribing commission and omission	Primary care, nursing home and hospital resi dents in Europe	A validated, reliable and comprehensive screening tool that can detect ADEs and when used as an intervention improves medication appropriateness [O’Mahony et al. 2010; Delgado Silveira et al. 2009; Lang et al. 2009; Ryan et al. 2009; Gallagher et al. 2008; Topinkova et al. 2008].
Falls Risk Increasing Drug (FRID) withdrawal	Intervention of removal of all potential FRID	Geriatric outpatient clinic	Effective as single intervention for falls prevention and significant costs saving for fall related treatment. Improvement of physical function tests upon withdrawal. [van der Velde et al. 2008, 2007a, 2007b]
Pharmacological measures of drug exposure
Polypharmacy	Multiple medication use	Community-dwelling, RACF and hospital residents	Predictor of drug–drug interactions, ADEs, use of PIMs, falls, hospitalization, nursing home placement and death, [Messinger-Rapport and Dumas, 2009; Frazier, 2005; Neutel et al. 2002; Colley and Lucas, 1993]
Drug Burden Index (DBI)	A measure of anticholinergic and sedative drugs using the principles of dose–response and maximal effect	Community-dwelling older people and residents of RACFs	Increasing DBI associated with impairments of physical and cognitive function in community-dwelling older people [Gnjidic et al. 2009; Hilmer et al. 2009, 2007a; Cao et al. 2008]. No association found with increasing DBI and functional impairments in RACFs [Wilson et al. 2010].
Central nervous system (CNS) acting medication	Number and summated standard daily dose of CNS	Well functioning community dwelling adults aged 70–79	Higher doses of CNS medications associated with repeat falls, cognitive decline and increased risk of future incident mobility limitation [Boudreau et al. 2009; Hanlon et al. 2009; Wright et al. 2009].
Anticholinergic Risk Scale (ARS)	Cumulative scale gives weight to each medication on a three- point scale based on the anti cholinergic potential of that drug	Geriatric evaluation and management (GEM) and primary care cohorts	Higher ARS scores had a statistically significant higher risk of anticholinergic adverse effects in the both cohorts [Rudolph et al. 2008].
Anticholinergic Drug Scale (ADS)	Cumulative scale gives weight to each medication on three- point scale based on the anti cholinergic potential of that drug	Residents of a rural long- term care facility	Associated with serum anticholinergic activity [Carnahan et al. 2006, 2002].
Serum Anticholinergic Activity (SAA)	A radioreceptor assay that quan tifies overall anticholinergic burden caused by drugs and their metabolites	Community-dwelling older people and several small geriatric patient groups	Associated with cognitive impairment or delirium in older patients independent of physical illness [Mulsant et al. 2003a, 2003b; Thienhaus et al. 1990].

ADE, adverse drug event; ADR, adverse drug reaction; PIMs, potentially inappropriate medicines; RACF, residential aged-care facility.

In 1991 the ‘Beers’ criteria’ for determining inappropriate drug use for nursing home residents were developed by an expert consensus panel [Beers et al. 1991]. With the cessation and emergence of particular drugs, this list has been refined and updated to include 48 different medications or classes of medications, as well as 20 diseases or conditions combined with medications to be avoided in older adults (PIPs) [Fick et al. 2003]. These highly cited, updated Beers’ criteria and subsequent variations of them have formed the basis for tools that aim to improve medication safety by measuring the risk and minimizing drug related problems in older people [O'Mahony and Gallagher, 2008; Rudd et al. 2005]. The Screening Tool for Older Persons’ Prescriptions (STOPP) and the Screening Tool to Alert Right Treatment (START) criteria have been developed and validated for European countries with results that indicate they are more sensitive to detecting ADE and prescription errors than the Beers’ criteria [O’Mahony et al. 2010; Delgado Silveira et al. 2009; Lang et al. 2009; Ryan et al. 2009; Gallagher et al. 2008; Topinkova et al. 2008]. The Drug Burden Index (DBI) is another risk assessment tool that identifies high-risk medicines by pharmacologic class (anticholinergic and sedative) and calculates an individual’s cumulative exposure to these medicines, considering both the number and dose of these medicines [Hilmer et al. 2007a]. The recently developed Anticholinergic Risk Scale (ARS) is a cumulative scale that gives weight to anticholinergic medications on a three-point scale (0, no or low risk, to 3, high anticholinergic potential). The ARS score for individuals is the sum of points for their medications [Rudolph et al. 2008]. Higher ARS scores have been shown to increase the risk of anticholinergic adverse effects of older people in primary care facilities (risk ratio [RR] = 1.9; 95% CI 1.5–2.5). Alternative methods to assess anticholinergic activity include measuring the individual drug or muscarinic acetylcholine receptor in vitro; however, they contain significant clinical limitations due to the highly variable pharmacokinetics of older people and between those in different settings [Rudd et al. 2005; Tune, 2000; Tune et al. 1992; Snyder and Yamamura, 1977].

Impairment of objective measures of physical function predicts loss of independence and mortality in older people [Guralnik et al. 1994]. The association of cumulative exposure to anticholinergic and sedative medicines with impaired physical function outcome measures in community dwelling older people is well documented [Gnjidic et al. 2009; Hilmer et al. 2009, 2007a; Landi et al. 2007]. Limited research has been undertaken in RACFs; however, a recent study in people from Australian RACFs showed that while there was high exposure to medicines in these classes (>60%), there was no association of exposure to anticholinergic and sedative medicines with objective measures of function [Wilson et al. 2010].

Falls are the most important risk factor for fractures in RACFs with over 50% of residents of aged-care facilities falling every year [Kannus et al. 2005]. Regardless of setting, the majority of studies have found that polypharmacy and exposure to specific drug classes are associated with an increased risk of recurrent and single falls [Tinetti and Kumar, 2010; Leipzig et al. 1999a, 1999b]. Specifically, exposure to antipsychotics [Hien le et al. 2005], selective serotonin reuptake inhibitors [Kallin et al. 2004; Arfken et al. 2001] and hypnotics [Avidan et al. 2005; Neutel et al. 2002] are established risk factors for falls in residents of nursing homes.

Hospitalization and death are further outcome measures that can be used to assess the safety of medications in RACFs. Some studies have found that residents of nursing homes who were exposed to PIPs were at a higher risk of hospitalization and death [Lau et al. 2005; Perri et al. 2005]. This is in contrast to a recent study in nursing homes which showed no association of increasing anticholinergic exposure with mortality after adjusting for covariates [Kumpula et al. 2010]. This latest study highlights the special cohort characteristics that researchers encounter when conducting trials in the frail institutionalized elderly. Multiple cormorbidities, high mortality and dementia rates, which can limit assessments, create cohort-specific characteristics different not only to community dwelling, but other nursing home populations.

Withdrawal

Safe drug withdrawal is an obvious option to decrease the prevalence of ADEs [Iyer et al. 2008]. Nursing home residents’ behaviour has been shown not to change when haloperidol, thioridazine and lorazepam were tapered to placebo [Cohen-Mansfield et al. 1999]. Interestingly, in this study a crossover method was used whereby individuals were tapered to the reverse drug schedule, with the active drugs swapped with a placebo and vice versa, with no affect on behaviour apparent. Discontinuation of long-term antipsychotics did not affect behavioural and psychological symptoms in a recent Norwegian study of older nursing home residents with dementia [Ruths et al. 2008]. A meta-analysis on medication reviews or educational interventions in long-term care facilities demonstrated a significant decrease in the use of hypnotic (OR = 0.57; 95% CI, 0.41–0.79) but not antipsychotic (OR = 0.81; 95% CI 0.63–1.04) medicines, yet any connection with health outcomes is unknown [Nishtala et al. 2008].

Pharmacist interventions

Tools that help identify patients at high risk of ADEs are commonplace in the hospital setting yet a more comprehensive system is needed for those who move into RACFs [Bates et al. 1999]. Initial research found that retrospective drug reviews undertaken by consultant pharmacists could save United States’ nursing homes billions of dollars for the treatment of drug-related problems [Bootman et al. 1997]. The ‘Fleetwood Project’ and subsequent ‘Fleetwood Model’ were created to demonstrate and assess the value of consultant pharmacists using prospective drug reviews and interventions, improved communications between patients and professionals, patient assessment by the pharmacist and care planning for patients at high risk of medication-related problems [Harms and Garrard, 1998]. Data from nursing homes that have implemented the Fleetwood Model show they have increased clinical interaction by pharmacists, increased time spent on the planning of pharmaceutical care, superior communication among the interdisciplinary team, more efficient processes within the nursing facility pharmacy and a reduced time spent on traditional drug reviews [Bain, 2007; Lapane and Hughes, 2006a]. An electronic screening tool, linked to the prescribing system for the dispensing pharmacy identified residents at the highest risk of ADEs [Lapane and Hughes, 2004]. In the intervention study over a 1-year period, the Fleetwood Model identified 2118 activities from 4272 individuals (9.48/100 resident months). The consulting pharmacist was involved in over 80% of these activities with the reasons for the interventions being laboratory test needed (13.1%), missing information/clarification needed (13%), unnecessary drug (10.3%), product selection opportunity (10.3%), and excessive duration alert (9.1%) [Lapane and Hughes, 2006b].

While the Fleetwood Model has been successful in the USA, the nursing home infrastructure differs greatly between countries and thus models must be adapted before broader application. Variations of the Fleetwood Model have been shown to decrease the prevalence of inappropriate psychoactive medications in a Northern Ireland population when compared with those who continued with normal care (OR 0.26; 95% CI 0.14–0.49) [Patterson et al. 2010].

Pharmacist interventions can have financial benefits with the North Carolina Long-Term Care Polypharmacy Initiative that targeted patients who had received 18 prescription refills in the last 90 days [Christensen et al. 2004]. They identified a US$21.63 per resident per month drug cost saving, reduction of drug alerts and reduction of the relative risk of hospitalization for those individuals who received a retrospective review [Trygstad et al. 2009].

Pharmacist interventions, or those where a pharmacist is part of a multidisciplinary team, have been found to reduce the amount of suboptimal prescribing in older people across a variety of settings [Castelino et al. 2009]. Pharmacist-conducted medication reviews for residents of aged-care facilities significantly reduce the prescription of sedative and anticholinergic medicines [Nishtala et al. 2009]. Furthermore, a multidisciplinary case conference involving the resident’s general practitioner, a geriatrician, a pharmacist and residential care staff member has been shown to be a feasible approach to improving the medication appropriateness without altering the resident’s behaviours in high-level RACFs [Crotty et al. 2004a]. Future research on pharmacy services is required to investigate what impact the reduction of PIPs has on clinical outcomes for residents and the healthcare system overall.

Technological advances

Technological advances in medical management should provide improvements in the safety of RACF residents. In Australia, the introduction of electronic prescribing to improve patient safety has been evaluated in a RACF [Bollen et al. 2005]. Electronic prescribing terminals with information on medications, medical history and allergies were trialled in a 100-bed RACF. Medical practitioners were encouraged to prescribe using the connected electronic software. A year after the system was introduced they showed significant reduction in the use of any medications based on electronic prescribing use and a decrease in quarterly fall rate. Practices seen in intensive care suggest a likely model with computerized physician orders to decrease errors and increase legibility, electronic alerts and reminders, barcode scanning and electronic medical records, which has been shown to prevent adverse events that may not have been picked up by older technologies or protocols [Forni et al. 2010]. Owing to the complex nature of medication management, the introduction of an electronic medication system that covers only one aspect of this treatment can cause problems [Scott-Cawiezell et al. 2009]. An observational study on the use of automated medication dispensing systems or ‘robots’ found not only problems with the administration and time errors but also errors arising after the medication was handled after removal from the robot [van den Bemt et al. 2009]. Technological advances must be used as an aid to give real-time patient data and to simplify decision making for the medical team, rather than a complete approach for medical management.

Training and supervision

Supervision and continuing education of RACF staff of all disciplines is an important component in patient safety, medical management of ADRs and reducing medication errors. Institutions such as the National Prescribing Service in Australia provide ongoing education to doctors, pharmacists and nurses on medication management for residents of aged-care facilities [National Prescribing Service in Australia, 2010]. Regulation by governments and professional bodies linked to registration/licensing to practice also ensures ongoing education. Less than satisfactory levels of supervision of student nurses has been highlighted as a leading cause of medication errors or near misses [Reid-Searl et al. 2008]. One-hour teaching sessions and self-directed learning packages have proven to statistically improve registered nurses’ knowledge of medication management [Lim et al. 2010]. Technology can also assist with training and supervision. Personal digital assistants (PDAs) have been tested in some nursing homes as a medical decision support system for nurses [Johansson et al. 2009]. These PDAs that scan barcodes have the potential to be a user-friendly, medical decision support system for nurses by increasing awareness of drug–drug interactions, patient medical history, therapeutic duplication and PIPs [Johansson et al. 2010].

Communication at the interfaces of care

Residents of aged-care facilities are at high risk of medication errors when transferred between the hospital setting and the RACF due to the changing of the medical management team. Medication reconciliation by doctors, pharmacists and nurses can reduce errors associated with patient transfers [Boockvar et al. 2004; Rozich et al. 2004; Pronovost et al. 2003]. Medication-management transfer summaries from hospitals, medication reviews by pharmacists and case conferences with physicians and pharmacists have been shown to be protective against worsening pain (RR = 0.55; 95% CI 0.32–0.94) and hospital usage (emergency department visits and hospital readmissions) (RR = 0.38; 95% CI 0.15–0.99), but not against adverse drug events, falls, worsening mobility, worsening behaviours or increased confusion [Crotty et al. 2004b].

Medication management and administration within the RACF

Nursing staff in the RACF are responsible for the safe storage and administration of medicines. Nurses play an important role in determining the administration of ‘take when required’ or ‘prn’ medications such as analgesics, hypnotics and laxatives. Their responsibilities include knowing when and why to give or withhold certain high-risk medications. Nurses who treat individuals with chronic pain for example, which is prevalent in 49–84% of nursing home residents, must follow strict guidelines with patient safety the priority [Bureau of Health Professions, 2010; Won et al. 2004]. Nurses also commonly encounter problems that can affect compliance such as residents having difficulty swallowing or refusing the medication. Usage of blister packs has been shown to improve compliance of medication in community-dwelling older people and is widely used in nursing homes by facility staff to reduce errors [Doggrell, 2010; Ware et al. 1991].

Conclusions

Medication therapies and the models of care for residents of nursing homes differ greatly to those of community-dwelling older people due to the different population characteristics. Specific intervention studies are required in nursing homes to decide on the best methods of tackling the high prevalence of ADEs and ADRs. A multidisciplinary approach between professional fields with good communication and ongoing research and education are essential. Technological advances are likely to contribute to medication safety in residential aged care. An increasing level of care will translate to an increasing level of costs. Long-term care facilities and their staff are likely to bear a large burden of the expenses and workload, whereas residents will enjoy a majority of the benefit [Subramanian et al. 2007].

Footnotes

Acknowledgement

The authors acknowledge the support of the Geoff and Elaine Penney Ageing Research Unit.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare that they have no conflicts of interest regarding this review.

References

Arfken

C.L.

Wilson

J.G.

Aronson

S.M.

(2001) Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 13: 85–91.

Avidan

A.Y.

Fries

B.E.

James

M.L.

Szafara

K.L.

Wright

G.T.

Chervin

R.D.

(2005) Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53: 955–962.

Avorn

Shrank

W.H.

(2008) Adverse drug reactions in elderly people: a substantial cause of preventable illness. BMJ 336: 956–957.

Bain

K.T.

(2007) Adverse drug reactions and current state of drug regimen review in nursing facilities: need for a change? Consult Pharm 22: 586–592.

Bates

D.W.

Miller

E.B.

Cullen

D.J.

Burdick

Williams

Laird

(1999) Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 159: 2553–2560.

Beers

M.H.

Ouslander

J.G.

Rollingher

Reuben

D.B.

Brooks

Beck

J.C.

(1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 151: 1825–1832.

Bergman

Olsson

Carlsten

Waern

Fastbom

(2007) Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scand J Prim Health Care 25: 9–14.

Bollen

Warren

Whenan

(2005) Introduction of electronic prescribing in an aged care facility. Aust Fam Physician 34: 283–287.

Boockvar

Fishman

Kyriacou

C.K.

Monias

Gavi

Cortes

(2004) Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 164: 545–550.

10.

Bootman

J.L.

Harrison

D.L.

Cox

(1997) The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 157: 2089–2096.

11.

Boudreau

R.M.

Hanlon

J.T.

Roumani

Y.F.

Studenski

S.A.

Ruby

C.M.

Wright

R.M.

(2009) Central nervous system medication use and incident mobility limitation in community elders: the Health, Aging, and Body Composition study. Pharmacoepidemiol Drug Saf 18: 916–922.

12.

Bureau of Health Professions (2010) State of Michigan Department of Community Health. Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain. http://www.michigan.gov/documents/mdch_nurseguidelinesusecspain_139444_7.pdf (accessed 12 August 2010).

13.

Cao

Y.J.

Mager

D.E.

Simonsick

E.M.

Hilmer

S.N.

Ling

S.M.

Windham

B.G.

(2008) Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 83: 422–429.

14.

Carnahan

R.M.

Lund

B.C.

Perry

P.J.

Culp

K.R.

Pollock

B.G.

(2002) The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull 36: 14–19.

15.

Carnahan

R.M.

Lund

B.C.

Perry

P.J.

Pollock

B.G.

Culp

K.R.

(2006) The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46: 1481–1486.

16.

Castelino

R.L.

Bajorek

B.V.

Chen

T.F.

(2009) Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother 43: 1096–1106.

17.

Catania

P.N.

(1998) Risk factors for drug-related problems in elderly ambulatory patients. Home Care Provid 3: 20–21, 24.

18.

Christensen

Trygstad

Sullivan

Garmise

Wegner

S.E.

(2004) A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 2: 248–256.

19.

Cohen-Mansfield

Lipson

Werner

Billig

Taylor

Woosley

(1999) Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159: 1733–1740.

20.

Colley

C.A.

Lucas

L.M.

(1993) Polypharmacy: the cure becomes the disease. J Gen Intern Med 8: 278–283.

21.

Crotty

Halbert

Rowett

Giles

Birks

Williams

(2004a) An outreach geriatric medication advisory service in residential aged care: a randomised controlled trial of case conferencing. Age Ageing 33: 612–617.

22.

Crotty

Rowett

Spurling

Giles

L.C.

Phillips

P.A.

(2004b) Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. Am J Geriatr Pharmacother 2: 257–264.

23.

Delgado Silveira

Munoz Garcia

Montero Errasquin

Sanchez Castellano

Gallagher

P.F.

Cruz-Jentoft

A.J.

(2009) [Inappropriate prescription in older patients: the STOPP/START criteria]. Rev Esp Geriatr Gerontol 44: 273–279.

24.

Doggrell

S.A.

(2010) Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging 27: 239–254.

25.

Edwards

I.R.

Aronson

J.K.

(2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255–1259.

26.

Fick

D.M.

Cooper

J.W.

Wade

W.E.

Waller

J.L.

Maclean

J.R.

Beers

M.H.

(2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 163: 2716–2724.

27.

Field

T.S.

Gurwitz

J.H.

Avorn

McCormick

Jain

Eckler

(2001) Risk factors for adverse drug events among nursing home residents. Arch Intern Med 161: 1629–1634.

28.

Field

T.S.

Gurwitz

J.H.

Harrold

L.R.

Rothschild

DeBellis

K.R.

Seger

A.C.

(2004) Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 52: 1349–1354.

29.

Fitzgerald

L.S.

Hanlon

J.T.

Shelton

P.S.

Landsman

P.B.

Schmader

K.E.

Pulliam

C.C.

(1997) Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother 31: 543–548.

30.

Forni

Chu

H.T.

Fanikos

(2010) Technology utilization to prevent medication errors. Curr Drug Saf 5: 13–18.

31.

Frazier

S.C.

(2005) Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 31: 4–11.

32.

Gallagher

Ryan

Byrne

Kennedy

O'Mahony

(2008) STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46: 72–83.

33.

Gnjidic

Cumming

R.G.

Le Couteur

D.G.

Handelsman

D.J.

Naganathan

Abernethy

D.R.

(2009) Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 68: 97–105.

34.

Guralnik

J.M.

Simonsick

E.M.

Ferrucci

Glynn

R.J.

Berkman

L.F.

Blazer

D.G.

(1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49: M85–M94.

35.

Gurwitz

J.H.

Field

T.S.

Avorn

McCormick

Jain

Eckler

(2000) Incidence and preventability of adverse drug events in nursing homes. Am J Med 109: 87–94.

36.

Gurwitz

J.H.

Sanchez-Cross

M.T.

Eckler

M.A.

Matulis

(1994) The epidemiology of adverse and unexpected events in the long-term care setting. J Am Geriatr Soc 42: 33–38.

37.

Hanlon

J.T.

Boudreau

R.M.

Roumani

Y.F.

Newman

A.B.

Ruby

C.M.

Wright

R.M.

(2009) Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci 64: 492–498.

38.

Hanlon

J.T.

Schmader

K.E.

Samsa

G.P.

Weinberger

Uttech

K.M.

Lewis

I.K.

(1992) A method for assessing drug therapy appropriateness. J Clin Epidemiol 45: 1045–1051.

39.

Harms

S.L.

Garrard

(1998) The Fleetwood Model: an enhanced method of pharmacist consultation. Consult Pharm 13: 1350–1355.

40.

Hien le

T.T.

Cumming

R.G.

Cameron

I.D.

Chen

J.S.

Lord

S.R.

March

L.M.

(2005) Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 53: 1290–1295.

41.

Hilmer

S.N.

Mager

D.E.

Simonsick

E.M.

Cao

Ling

S.M.

Windham

B.G.

(2007a) A drug burden index to define the functional burden of medications in older people. Arch Intern Med 167: 781–787.

42.

Hilmer

S.N.

Mager

D.E.

Simonsick

E.M.

Ling

S.M.

Windham

B.G.

Harris

T.B.

(2009) Drug burden index score and functional decline in older people. Am J Med 122: 1142–1149. e1141–1142.

43.

Hilmer

S.N.

McLachlan

A.J.

Le Couteur

D.G.

(2007b) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21: 217–230.

44.

Iyer

Naganathan

McLachlan

A.J.

Le Couteur

D.G.

(2008) Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 25: 1021–1031.

45.

Johansson

Petersson

Nilsson

(2009) A mobile medicine decision support system for district nurses. Stud Health Technol Inform 146: 516–520.

46.

Johansson

P.E.

Petersson

G.I.

Nilsson

G.C.

(2010) Personal digital assistant with a barcode reader–a medical decision support system for nurses in home care. Int J Med Inform 79: 232–242.

47.

Kallin

Gustafson

Sandman

P.O.

Karlsson

(2004) Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 16: 270–276.

48.

Kannus

Sievanen

Palvanen

Jarvinen

Parkkari

(2005) Prevention of falls and consequent injuries in elderly people. Lancet 366: 1885–1893.

49.

Kaur

Mitchell

Vitetta

Roberts

M.S.

(2009) Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging 26: 1013–1028.

50.

Kumpula

E.K.

Bell

J.S.

Soini

Pitkala

K.H.

(2010) Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol. in press.

51.

Landi

Russo

Liperoti

Cesari

Barillaro

Pahor

(2007) Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 81: 235–241.

52.

Lane

C.J.

Bronskill

S.E.

Sykora

Dhalla

I.A.

Anderson

G.M.

Mamdani

M.M.

(2004) Potentially inappropriate prescribing in Ontario community-dwelling older adults and nursing home residents. J Am Geriatr Soc 52: 861–866.

53.

Lang

P.O.

Hasso

Belmin

Payot

Baeyens

J.P.

Vogt-Ferrier

(2009) [STOPP-START: adaptation of a French language screening tool for detecting inappropriate prescriptions in older people.]. Can J Public Health 100: 426–431.

54.

Lapane

K.L.

Hughes

C.M.

(2004) Identifying nursing home residents at high risk for preventable adverse drug events: Modifying a tool for use in the Fleetwood phase III study. Consult Pharm 21: 533–539.

55.

Lapane

K.L.

Hughes

C.M.

(2006a) Adherence to the components of the Fleetwood model: self-reported process measures in the Fleetwood Phase III study. Consult Pharm 21: 981–987.

56.

Lapane

K.L.

Hughes

C.M.

(2006b) Pharmacotherapy interventions undertaken by pharmacists in the Fleetwood phase III study: the role of process control. Ann Pharmacother 40: 1522–1526.

57.

Laroche

M.L.

Charmes

J.P.

Nouaille

Picard

Merle

(2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63: 177–186.

58.

Lau

D.T.

Kasper

J.D.

Potter

D.E.

Lyles

Bennett

R.G.

(2005) Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med 165: 68–74.

59.

Leipzig

R.M.

Cumming

R.G.

Tinetti

M.E.

(1999a) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47: 30–39.

60.

Leipzig

R.M.

Cumming

R.G.

Tinetti

M.E.

(1999b) Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 47: 40–50.

61.

Lim

L.M.

Chiu

L.H.

Dohrmann

Tan

K.L.

(2010) Registered nurses' medication management of the elderly in aged care facilities. Int Nurs Rev 57: 98–106.

62.

Lund

B.C.

Carnahan

R.M.

Egge

J.A.

Chrischilles

E.A.

Kaboli

P.J.

(2010) Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 44: 957–963.

63.

Messinger-Rapport

Dumas

L.G.

(2009) Falls in the nursing home: a collaborative approach. Nurs Clin North Am 44: 187–195.

64.

Mulsant, B.H., Gharabawi, G., Bossie, C., Mao, L., Kirshnerm, M. and Pollock, B.G. (2003a) Does anticholinergic burden differ in elderly patients with dementia receiving risperidone or olanzapine? Presented at the Annual Scientific meeting of the American Geriatrics Society, Baltimore, MD, 14–18 May 2003.

65.

Mulsant

B.H.

Pollock

B.G.

Kirshner

Shen

Dodge

Ganguli

(2003b) Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 60: 198–203.

66.

National Prescribing Service in Australia (2010) http://www.nps.org.au (accessed 24 June 2010).

67.

Neutel

C.I.

Perry

Maxwell

(2002) Medication use and risk of falls. Pharmacoepidemiol Drug Saf 11: 97–104.

68.

Nishtala

P.S.

Hilmer

S.N.

McLachlan

A.J.

Hannan

P.J.

Chen

T.F.

(2009) Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging 26: 677–686.

69.

Nishtala

P.S.

McLachlan

A.J.

Bell

J.S.

Chen

T.F.

(2008) Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry 16: 621–632.

70.

O'Mahony

Gallagher

P.F.

(2008) Inappropriate prescribing in the older population: need for new criteria. Age Ageing 37: 138–141.

71.

O’Mahony

Gallagher

Ryan

Byrne

Hamilton

Barry

(2010) STOPP & START criteria: A new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med 1: 45–51.

72.

Patterson

S.M.

Hughes

C.M.

Crealey

Cardwell

Lapane

K.L.

(2010) An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study). J Am Geriatr Soc 58: 44–53.

73.

Perri

III Menon

A.M.

Deshpande

A.D.

Shinde

S.B.

Jiang

Cooper

J.W.

(2005) Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother 39: 405–411.

74.

Pronovost

Weast

Schwarz

Wyskiel

R.M.

Prow

Milanovich

S.N.

(2003) Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care 18: 201–205.

75.

Rancourt

Moisan

Baillargeon

Verreault

Laurin

Gregoire

J.P.

(2004) Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr 4: 9.

76.

Reid-Searl

Moxham

Walker

Happell

(2008) Shifting supervision: implications for safe administration of medication by nursing students. J Clin Nurs 17: 2750–2757.

77.

Rozich

J.D.

Howard

R.J.

Justeson

J.M.

Macken

P.D.

Lindsay

M.E.

Resar

R.K.

(2004) Standardization as a mechanism to improve safety in health care. Jt Comm J Qual Saf 30: 5–14.

78.

Rudd

K.M.

Raehl

C.L.

Bond

C.A.

Abbruscato

T.J.

Stenhouse

A.C.

(2005) Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 25: 1592–1601.

79.

Rudolph

J.L.

Salow

M.J.

Angelini

M.C.

McGlinchey

R.E.

(2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168: 508–513.

80.

Ruggiero

Lattanzio

Dell'Aquila

Gasperini

Cherubini

(2009) Inappropriate drug prescriptions among older nursing home residents: the Italian perspective. Drugs Aging 26(Suppl. 1): 15–30.

81.

Ruths

Straand

Nygaard

H.A.

Aarsland

(2008) Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study–the Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry 23: 889–895.

82.

Ryan

O'Mahony

Kennedy

Weedle

Byrne

(2009) Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 68: 936–947.

83.

Scott-Cawiezell

Madsen

R.W.

Pepper

G.A.

Vogelsmeier

Petroski

Zellmer

(2009) Medication safety teams' guided implementation of electronic medication administration records in five nursing homes. Jt Comm J Qual Patient Saf 35: 29–35.

84.

Snyder

S.H.

Yamamura

H.I.

(1977) Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34: 236–239.

85.

Steinman

M.A.M.D.

Rosenthal

G.E.M.D.

Landefeld

C.S.M.D.

Bertenthal

D.M.P.H.

Sen

S.P.

Kaboli

P.J.M.D.

(2007) Conflicts and concordance between measures of medication prescribing quality. Medical Care 45: 95–99.

86.

Subramanian

Hoover

Gilman

Field

T.S.

Mutter

Gurwitz

J.H.

(2007) Computerized physician order entry with clinical decision support in long-term care facilities: costs and benefits to stakeholders. J Am Geriatr Soc 55: 1451–1457.

87.

Thienhaus

O.J.

Allen

Bennett

J.A.

Chopra

Y.M.

Zemlan

F.P.

(1990) Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 240: 28–33.

88.

Tinetti

M.E.

Kumar

(2010) The patient who falls: “It's always a trade-off”. JAMA 303: 258–266.

89.

Topinkova

Madlova

Fialova

Klan

(2008) [New evidence-based criteria for evaluating the appropriateness of drug regimen in seniors. Criteria STOPP (screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment)]. Vnitr Lek 54: 1161–1169.

90.

Trygstad

T.K.

Christensen

D.B.

Wegner

S.E.

Sullivan

Garmise

J.M.

(2009) Analysis of the North Carolina long-term care polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting. Clin Ther 31: 2018–2037.

91.

Tune

Carr

Hoag

Cooper

(1992) Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 149: 1393–1394.

92.

Tune

L.E.

(2000) Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 5: 149–153.

93.

van den Bemt

P.M.

Idzinga

J.C.

Robertz

Kormelink

D.G.

Pels

(2009) Medication administration errors in nursing homes using an automated medication dispensing system. J Am Med Inform Assoc 16: 486–492.

94.

van der Velde

Meerding

W.J.

Looman

C.W.

Pols

H.A.

van der Cammen

T.J.

(2008) Cost effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 25: 521–529.

95.

van der Velde

Stricker

B.H.

Pols

H.A.

van der Cammen

T.J.

(2007a) Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 63: 232–237.

96.

van der Velde

Stricker

B.H.

Pols

H.A.

van der Cammen

T.J.

(2007b) Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging 24(8): 691–699.

97.

Ware

G.J.

Holford

N.H.

Davison

J.G.

Harris

R.G.

(1991) Unit dose calendar packaging and elderly patient compliance. N Z Med J 104: 495–497.

98.

Wilson

N.M.

Hilmer

S.N.

March

L.M.

Cameron

I.D.

Lord

S.R.

Seibel

M.J.

(2010) Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing 39(4): 503–507.

99.

Won

A.B.

Lapane

K.L.

Vallow

Schein

Morris

J.N.

Lipsitz

L.A.

(2004) Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc 52: 867–874.

100.

Wright

R.M.

Roumani

Y.F.

Boudreau

Newman

A.B.

Ruby

C.M.

Studenski

S.A.

(2009) Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition Study. J Am Geriatr Soc 57: 243–250.

Medication safety in residential aged-care facilities: a perspective

Abstract

Keywords

Background

Epidemiology

Risk assessment tools

Withdrawal

Pharmacist interventions

Technological advances

Training and supervision

Communication at the interfaces of care

Medication management and administration within the RACF

Conclusions

Footnotes

Acknowledgement

Funding

Conflict of interest statement

References